1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Suheung Co., Ltd.

Suheung Co., Ltd.

008490.KS
Suheung Co., Ltd.KR flagKorea Exchange
20,100.00
KRW
-350.00
- -
223.84BMarket Cap
Suheung Co., Ltd.
008490.KS
(Korea Exchange)

Recent

price

20,100.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
18,026.26
16,781.28
18,290.15
23,664.19
25,166.5
26,283.02
29,414.9
30,259.3
35,211.04
41,440.54
49,730.21
53,672.45
57,098.08
53,440.08
58,764.41
64,958.23
66,789.57
Revenue per Share
1,172
1,602.81
-383
1,073
1,846
1,974
2,360
1,995
2,303
2,853
4,766
4,829
3,056
550
1,644
3,911
4,438.24
Basic EPS, GAAP
-3,974.79
-8,094.02
-3,902.92
-2,967.19
-846.31
-917.45
1,258.91
-92.49
-1,114.37
-2,300.35
-652.52
2,575.6
-1,013.54
-3,754.47
1,570.26
2,662.68
1,676.53
Free Cash Flow per Basic Share
250
327.91
317.88
192.64
264.86
257.37
272.19
478.31
485.79
941.29
451.36
656.31
499.93
400.17
254.77
663.15
200.94
Dividend per Share
8,051.79
13,140.64
12,198.87
12,972.04
14,351.52
16,042.05
18,003.02
19,480.54
21,944.36
24,555.32
29,101.61
33,253.78
35,850.94
36,214.09
37,890.11
42,090.69
42,632.39
Book Value per Share
17,558.47
18,056.41
17,086.42
18,562.51
19,909.92
22,139.84
24,233.96
25,358.06
26,611.14
28,866.15
33,224.02
38,026.04
41,705.97
42,339.44
45,280.25
48,152.22
49,513.75
Tangible Book Value per Share
11
11
11
11
12
12
12
12
11
11
11
11
11
11
11
11
11
Basic Weighted Avg Shares
199,537
187,869
207,026
269,989
291,116
304,124
340,361
350,008
393,476
460,728
553,012
596,733
634,966
594,567
653,264
722,309
743,019
Sales/Revenue/Turnover
14.56
14.32
6.97
9.32
10.01
11.13
11.79
10.65
9.99
10.29
13.44
11.66
9.76
7.23
5.18
7.02
8.13
Operating Margin (%)
11,486
7,797
14,834
18,515
18,845
20,734
23,630
24,997
26,654
29,830
34,357
38,187
35,548
36,434
39,855
40,595
40,619
Depreciation Expense
12,973
17,944
-4,335
12,242
21,354
22,841
27,308
23,076
25,736
31,719
52,999
53,689
33,985
6,119
18,276
43,489
49,374
Net Income, GAAP
37.04
19.76
- -
15.72
10.28
8.59
8.96
14.73
16.24
16.75
17.87
20.78
21.85
36.67
30.98
12.32
14.74
Effective Tax Rate (%)
6.5
9.55
-2.09
4.53
7.34
7.51
8.02
6.59
6.54
6.88
9.58
9
5.35
1.03
2.8
6.02
6.65
Profit Margin (%)
-3,914
-11,363
92,420
48,493
45,439
73,697
54,056
-5,129
20,097
68,262
46,760
82,229
118,628
-10,263
65,429
97,453
87,293
Working Capital
42,015
101,420
177,375
118,753
111,745
147,187
119,746
72,096
118,577
176,902
117,107
137,540
172,933
74,237
125,069
144,864
129,112
LT Debt
195,704
208,862
199,953
218,229
237,288
263,042
288,439
300,841
308,172
328,995
376,982
429,868
469,724
477,069
507,774
541,017
556,403
Total Equity
6.46
5.87
- -
4.9
5.86
6.34
6.9
5.84
5.82
6.39
8.84
7.33
5.85
2.99
2.46
4.61
5.27
Return on Invested Capital (%)
9.53
6.52
- -
4.61
6.8
5.93
6.1
5.14
5.45
5.76
8.04
7.4
4.5
1.78
3.2
5.88
6.12
Return on Capital (%)
15.33
15.19
-3.04
8.56
13.6
12.99
13.86
10.64
10.94
12.24
17.77
15.49
8.85
1.53
4.44
9.78
10.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
303,554
290,216
318,440
LT Borrowings
125,062
143,764
128,087
LT Finance Leases
1,103
1,101
1,025
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
300,228
240,738
205,252

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
451,976
464,696
480,370
Cash, Cash Equivalents & STI
63,798
58,678
67,427
Accounts Receivable, Net
128,165
114,177
137,550
Inventories
233,535
269,885
252,819
Total Current Liabilities
367,110
367,243
393,077
Payables & Accruals
- -
- -
- -
ST Debt
303,554
290,216
318,440
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.56%
7.57%
6.55%
Free Cash Flow
31.77%
-87.11%
69.61%
Net Income, GAAP
32.51%
43.85%
137.96%
Sales/Revenue/Turnover
9.27%
5.68%
10.57%
Total Cash Common Dividend
24.59%
25.12%
160.36%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
165,340
172,765
166,593
148,566
653,264
2025
180,841
190,021
185,046
166,400
722,309
2026
201,552
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
460
170
957
- -
1,644
2025
533
2,153.13
807.82
- -
3,911
2026
1,060.78
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
154.62
99.74
- -
- -
254.77
2025
462.61
200.51
-0.01
- -
663.15
2026
0.53
- -
- -
- -
- -
Similar Companies
Cannabis Global Inc. (CBGL)
Glenmark Life Sciences Limited (GLS.NS)
High Fusion Inc. (SPLIF)
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ)
Medicure Inc. (MCUJF)
Dermapharm Holding SE (DMP.DE)
Business
Suheung Co., Ltd. (008490.KS) manufactures and sells hard and soft capsules for the pharmaceutical, nutraceutical, and health supplement industries. The company produces empty two-piece hard capsules under the Embocaps brand; soft gelatin capsules; solid dosage forms including tablets, powders, and granules; semi-solid forms such as fluidity and concentrated liquids; and jelly products like gummies, sticky, and water jellies. It also offers medical supplies encompassing prescription medicines, over-the-counter drugs such as antipyretic-analgesics, cold medicines, digestive medicines, liver-treatment medicines, and nutritional supplements; quasi-drugs including low-content vitamin-cosmetic products, multi-vitamins, toothpaste, effervescent tablets, and chewable tablets; and raw materials like gelatins and collagens used in capsules, adhesives, cosmetics, and food. Founded in 1973 and headquartered in Cheongju-si, South Korea, at 61 Osongsaengmyeong-ro, Suheung operates through two main segments—capsules and gelatin—with approximately 742 employees and vertically integrated production facilities including the Osong plant. The company serves domestic Korean markets and exports to global pharmaceutical clients, positioning itself as a key supplier of high-quality empty capsules and contract manufacturing services with regulatory support and packaging solutions. Its operations emphasize cutting-edge technology, productivity, and compliance for sectors like drug manufacturers-specialty and generic, specialty chemicals, and healthcare. In recent developments, Suheung launched EMBOCAPS AP60 in May 2024, a delayed-release hard capsule offering over 60 minutes of acid protection using a patented hypromellose and pectin blend without shellacs, phthalates, or coatings, aimed at safeguarding sensitive ingredients like probiotics; this innovation supports expanded production via a new Alpha plant. The company continues strategic efforts outlined in its 2023 Sustainability Report to establish a global comprehensive materials business foundation in 2024 through targeted growth strategies. Suheung maintains its focus on R&D, quality innovation, and market leadership without reported major acquisitions, partnerships, or reorganizations in the last 1-2 years.